Lung Cancer Clinical Trials in Houston

Showing 221-240 of 537 trials

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

NCT04969315

The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care. The main questions it aims to answer are: 1. To evaluate the safety and tolerability of TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) 2. To determine the maximum tolerated dose or the recommended phase 2 dose of TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) 3. To obtain a preliminary estimate of efficacy of TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in advanced solid tumors.

Renal Cell CancerCastrate Resistant Prostate CancerNon Small Cell Lung Cancer+4 more

Portage Biotech90 participantsStarted Jun 2023

Los Angeles, California, United States • Louisville, Kentucky, United States • Houston, Texas, United States

COMPLETEDPhase 1< 1 mile

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

NCT03894618

This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.

Squamous Cell Carcinoma of the Head and NeckMelanomaNon Small Cell Lung Cancer+10 more

Shattuck Labs, Inc.49 participantsStarted Mar 2019

Nashville, Tennessee, United States • Houston, Texas, United States • Leuven, Belgium +2 more locations

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Lung Cancer Trials in Other Cities

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Phase Ib of L-NMMA and Pembrolizumab

Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Study of LP-184 in Patients With Advanced Solid Tumors

Pulmonary Rehabilitation Before Lung Cancer Resection

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Other Conditions in Houston